Fifty 410: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fifty410.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Fifty 410” on the pictured label, suggesting Fifty 410 is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Fifty 410 is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

2. 2

   “Additionally, the following claim concerning compounded semaglutide and tirzepatide products appears on your website:”

3. 3

   ““clinically proven ingredients””

4. 4

   “Compounded drug products are not FDA-approved. Your claim implies that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.fifty410.com returned a live storefront on 2026-08-09 titled "GLP-1 Weight Loss Medication Online | Fifty 410", advertising "100k+ customers", listing compounded semaglutide and tirzepatide "Starting at $199 /month" alongside hair, NAD+ and sermorelin products, with a working sign-up flow — an operating seller. The phrase "clinically proven" did not appear in the homepage as fetched.

Strip out every brand name and you still have a claim. That is what this letter demonstrates, and it is why it is the most useful one in the roster for reading marketing copy generally. "Clinically proven ingredients" mentions no product, makes no comparison and could be written by someone deliberately avoiding trademarks — and FDA held it implies the products "have been FDA-approved or otherwise evaluated for safety and effectiveness". The reason is that clinical proof is a property of a studied product at a studied dose, not of a substance in the abstract. Semaglutide has been proven in trials; a compounded semaglutide preparation of some strength, from some facility, has not been in those trials, and inheriting the evidence is the same borrowing as inheriting the name, just done without the name. Pair it with the other finding — the vial carried the seller's name, not the compounder's — and both halves of the provenance question come out wrong: what made this, and what is it proven to do. Neither finding says anything about whether the medication is safe or well made. The site is trading today at a headline of $199 a month, and "clinically proven" no longer appears on its front page.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Fifty 410 failed to respond.